Detalles de la búsqueda
1.
Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
Ann Rheum Dis
; 80(11): 1400-1409, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33926921
2.
Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission.
Rheumatology (Oxford)
; 60(12): 5549-5559, 2021 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33748831
3.
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.
Ann Rheum Dis
; 78(2): 192-200, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30396903
4.
Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care - 2-year outcomes and predictors.
Rheumatology (Oxford)
; 58(1): 110-119, 2019 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30169706
5.
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.
Ann Rheum Dis
; 76(8): 1426-1431, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28473425
6.
Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries.
Ann Rheum Dis
; 79(6): 846-848, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32111583
7.
Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci.
Ann Rheum Dis
; 79(2): e14, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30573653
8.
Response to ''To switch or not to switch': the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al.
Ann Rheum Dis
; 79(4): e37, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30674476
9.
Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO.
Rheumatology (Oxford)
; 53(11): 2100-9, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24939677
10.
Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.
Ann Rheum Dis
; 72(7): 1149-55, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22941767
11.
Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry.
RMD Open
; 8(2)2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36418087
12.
Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors.
RMD Open
; 8(2)2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36549857
13.
Association between MRI findings and patient-reported outcomes in patients with rheumatoid arthritis in clinical remission and at relapse.
Int J Rheum Dis
; 23(4): 488-498, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31994328
14.
Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish National Patient Registry.
Clin Epidemiol
; 9: 627-632, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29238225
15.
Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial.
Clin Rheumatol
; 36(4): 781-789, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27921185
Resultados
1 -
15
de 15
1
Próxima >
>>